Nose-to-brain delivery of octreotide acetate in situ gel for pituitary adenoma: Pharmacological and in vitro cytotoxicity studies

Gadhave, Dnyandev; Khot, Shubham; Tupe, Shrikant; Shinde, Mahesh; Tagalpallewar, Amol; Gorain, Bapi; Kokare, Chandrakant

doi:10.1016/j.ijpharm.2022.122372

Cited by 8 publications

(2 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… The ISG (IN) showed higher DTE and DTP than the free drug solution (IV). [ 100 ] Tranexamic acid (epistaxis) Chitoclear FG and glycerophosphate Tsg 32°C, GT 5 min Viscosity 0.15 and 269 Pa·s before and after gelation The ISG spray (IN) performances as the final dosage form were estimated: ovality ratio of 1.07; median droplet size of 99.7 μm, satisfying FDA and EMA criteria (30–120 μm). A prolonged contact time on the nasal cavity was observed for the ISG by the nasal deposition profile.…”

Section: Strategies To Improve Drug Delivery Via the Intranasal Routementioning

confidence: 99%

“…13 Poloxamer ® 407 (also known as Pluronic ® F127) is a commonly used temperature-sensitive gelling agent that consists of hydrophilic end groups (PEO) and hydrophobic core groups (PPO). [98][99][100]102,103 With increasing temperature, the PPO block is dehydrated, which causes water expulsion from the micelle core, inducing gelation.…”

Section: Mechanism Of Sol-gel Transitionmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Intranasal Administration for Brain-Targeting Delivery: A Comprehensive Review of Lipid-Based Nanoparticles and Stimuli-Responsive Gel Formulations

Koo,

Lim,

2024

IJN

View full text Add to dashboard Cite

Addressing disorders related to the central nervous system (CNS) remains a complex challenge because of the presence of the blood-brain barrier (BBB), which restricts the entry of external substances into the brain tissue. Consequently, finding ways to overcome the limited therapeutic effect imposed by the BBB has become a central goal in advancing delivery systems targeted to the brain. In this context, the intranasal route has emerged as a promising solution for delivering treatments directly from the nose to the brain through the olfactory and trigeminal nerve pathways and thus, bypassing the BBB. The use of lipid-based nanoparticles, including nano/microemulsions, liposomes, solid lipid nanoparticles, and nanostructured lipid carriers, has shown promise in enhancing the efficiency of nose-to-brain delivery. These nanoparticles facilitate drug absorption from the nasal membrane. Additionally, the in situ gel (ISG) system has gained attention owing to its ability to extend the retention time of administered formulations within the nasal cavity. When combined with lipid-based nanoparticles, the ISG system creates a synergistic effect, further enhancing the overall effectiveness of brain-targeted delivery strategies. This comprehensive review provides a thorough investigation of intranasal administration. It delves into the strengths and limitations of this specific delivery route by considering the anatomical complexities and influential factors that play a role during dosing. Furthermore, this study introduces strategic approaches for incorporating nanoparticles and ISG delivery within the framework of intranasal applications. Finally, the review provides recent information on approved products and the clinical trial status of products related to intranasal administration, along with the inclusion of quality-by-design–related insights.

show abstract